Stocks · Healthcare · Biotechnology
Janux Therapeutics, Inc. JANX
$16.93 -0.18% Close, Oct 2, 2026 · NASDAQ · Market cap $1.03B
Strong growth
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $31.9M, up 7162.0% from a year earlier, accelerating from 131.5% a quarter earlier.
- Operating margin widened to -450.3% from -33002.1% a year earlier.
- The stock is in an uptrend: above its 200-day average for 34 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 1%
- Revenue growth, 3-year CAGRBottom 38%
- Revenue growth accelerationTop 1%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 46%
- Gross marginTop 44%
- Operating marginBottom 17%
- Accruals (lower is better)Bottom 42%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 46%
- Free-cash-flow yieldBottom 49%
- EBITDA / enterprise valueBottom 39%
- Sales / enterprise valueBottom 15%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 25%
- 6-month returnTop 44%
- 1-year return vs S&P 500Bottom 24%
- Distance from 52-week highBottom 26%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 37%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 47%
- Upside to consensus price targetTop 48%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 31%
- Maximum drawdown, 3 yearsBottom 29%
- Beta vs S&P 500 (lower is better)Bottom 48%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 131.5% | 7162.0% | ↑ |
| Gross margin | -17533.3% | 68.9% | ↑ |
| Operating margin | -33002.1% | -450.3% | ↑ |
| FCF margin | -13827.8% | -171.1% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 7162.0% | 131.5% | ↑ | Top 1% |
| Gross margin | 68.9% | -17533.3% | ↑ | Top 44% |
| Operating margin | -450.3% | -33002.1% | ↑ | Bottom 17% |
| Net margin | -321.8% | -24064.0% | ↑ | — |
| Free-cash-flow margin | -171.1% | -13827.8% | ↑ | — |
| Return on invested capital | -15.1% | — | Top 46% | |
| Revenue growth, 3-year CAGR | 5.1% | — | Bottom 38% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 144.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -7150.8 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.24%
- Shareholder yield
- -1.24%
- Share count change, 1 year
- +1.7%
- Share count change, 3-year CAGR
- +14.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +10.6%
- Average 2-day reaction, last 8
- -0.2%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $28.25
- Target vs current price
- +66.9%
- Analysts with a rating
- 16
- Share rating Buy or Strong Buy
- 75%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -39.3% | +0.6% | +4.2% | +23.1% | — |
| May 7, 2026 | +25.0% | -0.5% | -0.1% | -5.9% | +4.8% |
| Feb 26, 2026 | +21.5% | +0.7% | +4.7% | +0.7% | +5.2% |
| Nov 6, 2025 | +35.0% | +4.1% | +3.6% | -40.5% | -49.9% |
| Aug 7, 2025 | -14.6% | -6.6% | +3.2% | -1.0% | +17.9% |
| May 8, 2025 | +11.6% | +2.6% | -12.0% | -3.7% | -7.0% |
| Feb 27, 2025 | +26.5% | -1.8% | -3.4% | -7.6% | -22.7% |
| Nov 6, 2024 | -37.8% | -0.7% | -4.4% | +20.9% | -25.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.35 | -$0.25 | -39.3% | $10.3M |
| May 7, 2026 | -$0.39 | -$0.52 | +25.0% | $3.7M |
| Feb 26, 2026 | -$0.51 | -$0.65 | +21.5% | $7.9M |
| Nov 6, 2025 | -$0.39 | -$0.60 | +35.0% | $10.0M |
| Aug 7, 2025 | -$0.55 | -$0.48 | -14.6% | — |
| May 8, 2025 | -$0.38 | -$0.43 | +11.6% | — |
| Feb 27, 2025 | -$0.36 | -$0.49 | +26.5% | — |
| Nov 6, 2024 | -$0.51 | -$0.37 | -37.8% | $439,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 32.17× | — | — | Bottom 15% |
| Free-cash-flow yield | -5.28% | — | — | Bottom 49% |
| Earnings yield | -9.69% | — | — | Bottom 46% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 34
- 50-day average slope (20 days)
- +3.8%
- 200-day average slope (20 days)
- -4.0%
- Distance from 50-day average
- -0.9%
- Distance from 200-day average
- +12.9%
- RSI (14)
- 47.6
- Relative volume
- 0.83×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 45.7%
- Volatility vs own 5-year history
- 8th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.15
- Correlation with S&P 500
- 0.25
- Current drawdown from 1-year high
- -51.3%
- Maximum drawdown, 3 years
- -81.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Aug 5, 2021 | Nov 9, 2023 | -83.1% | 570 days | 73 days (Feb 27, 2024) |
| Dec 4, 2024 | Feb 5, 2026 | -81.8% | 292 days | Not yet recovered |
| May 3, 2024 | Aug 7, 2024 | -45.5% | 65 days | 83 days (Dec 4, 2024) |
| Feb 27, 2024 | Apr 5, 2024 | -29.4% | 27 days | 4 days (Apr 11, 2024) |
| Jun 11, 2021 | Jun 15, 2021 | -26.1% | 2 days | 10 days (Jun 29, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.03B
- EPS, diluted (TTM)
- -$1.64
- Revenue (TTM)
- $31.9M
- 52-week range
- $12.12 – $35.34
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $3.6M | $8.6M | $8.1M | $10.6M | $10.0M |
| Gross profit | -$22.6M | $7.8M | $6.1M | $8.5M | $8.0M |
| Operating income | -$32.9M | -$67.1M | -$73.0M | -$98.8M | -$157.7M |
| Net income | -$32.7M | -$63.1M | -$58.3M | -$69.0M | -$113.6M |
| EPS (diluted) | -$0.79 | -$1.52 | -$1.32 | -$1.28 | -$1.83 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $439,000 | $0 | $0 | $0 | $10.0M | $7.9M | $3.7M | $10.3M |
| Net income | -$28.1M | -$20.2M | -$23.5M | -$33.9M | -$24.3M | -$31.9M | -$24.4M | -$22.0M |
| EPS (diluted) | -$0.51 | -$0.36 | -$0.38 | -$0.55 | -$0.39 | -$0.51 | -$0.39 | -$0.35 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$17.0M | -$42.9M | -$50.6M | -$43.8M | -$82.2M |
| Capital expenditure | -$1.5M | -$6.4M | -$1.9M | -$359,000 | -$1.0M |
| Free cash flow | -$18.5M | -$49.4M | -$52.4M | -$44.2M | -$83.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $204.2M | $500,000 | $56.5M | $698.3M | $4.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $970.9M
- Total assets
- $1.01B
- Total liabilities
- $79.7M
- Total debt
- $21.0M
- Net debt
- -$6.8M
- Shareholders’ equity
- $928.0M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 5,891,965
- Days to cover
- 5.89
- Change vs previous report
- -2.8%
FINRA short interest, settlement date Sep 15, 2026.